- Conditions
- Head And Neck Cancer
- Interventions
- Erlotinib, RAD001
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 71
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Breast Cancer
- Interventions
- Fulvestrant, erlotinib, Placebo
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 6
- States / cities
- Jonesboro, Arkansas • Little Rock, Arkansas • Springdale, Arkansas + 3 more
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- Dasatinib, Erlotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Non Small Cell Lung Cancer, Failed Prior Chemotherapy
- Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774)
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Tarceva (Trademark) (erlotinib HCl, OSI-774), Combination carboplatin and paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 19
- States / cities
- Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- CP-461
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 5
- States / cities
- Orlando, Florida • Albany, New York • Dallas, Texas + 2 more
- Conditions
- Prostatic Neoplasms
- Interventions
- Exisulind
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Interventions
- FOLFOX, 5-FU, Erlotinib
- Drug
- Lead sponsor
- Translational Oncology Research International
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- NSCLC
- Interventions
- Exisulind
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Chicago, Illinois
- Conditions
- Colorectal Cancer
- Interventions
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Biological · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 10
- States / cities
- Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
- Conditions
- Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Interventions
- OSI-7904L
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas • Salt Lake City, Utah
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pazopanib, Erlotinib
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 8
- States / cities
- Fort Myers, Florida • Lawrenceville, Georgia • Cincinnati, Ohio + 5 more
- Conditions
- Prostate Cancer
- Interventions
- CP-461
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- New York, New York • Seattle, Washington
- Conditions
- Bronchioloalveolar Carcinoma, Large Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pemetrexed Disodium
- Drug · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 5
- States / cities
- Sacramento, California • Worcester, Massachusetts • The Bronx, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- bevacizumab, Erlotinib
- Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Galloway, New Jersey • Mount Holly, New Jersey • Paoli, Pennsylvania + 2 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Erlotinib, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Locally Advanced or Metastatic Adenoca of the Biliary Tract
- Interventions
- OSI-7904L, 5-Fluorouracil/Leucovorin
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 3 more
- Conditions
- Bladder Cancer
- Interventions
- Erlotinib, Radical Cystectomy
- Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Liver Cancer
- Interventions
- Bevacizumab, Erlotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Psoriasis
- Interventions
- erlotinib, placebo tablet
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pancreatic Cancer
- Interventions
- Tarceva (erlotinib HCl, OSI-774)
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 569 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 60
- States / cities
- Tucson, Arizona • Springdale, Arkansas • Berkeley, California + 51 more
- Conditions
- Head and Neck Cancer, Pharynx Cancer
- Interventions
- Chemoradiotherapy, Cisplatin, Bevacizumab, Erlotinib
- Radiation · Drug
- Lead sponsor
- David M. Brizel, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- erlotinib, gemcitabine, nab-paclitaxel
- Drug
- Lead sponsor
- OSI Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 5
- States / cities
- Palm Springs, California • Aurora, Colorado • Chapel Hill, North Carolina + 2 more
- Conditions
- Malignant Melanoma
- Interventions
- CP-461
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 1
- States / cities
- New York, New York